{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T07:52:17Z","timestamp":1789199537787,"version":"build-2803163510"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2016,11,17]],"date-time":"2016-11-17T00:00:00Z","timestamp":1479340800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1007\/s00277-016-2877-6","type":"journal-article","created":{"date-parts":[[2016,11,17]],"date-time":"2016-11-17T13:04:44Z","timestamp":1479387884000},"page":"245-251","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Gemcitabine, dexamethasone, and cisplatin (GDP) as salvage chemotherapy for patients with relapsed or refractory peripheral T cell lymphoma\u2014not otherwise specified"],"prefix":"10.1007","volume":"96","author":[{"given":"Fei","family":"Qi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yexiong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianliang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Gui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changgong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengyu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuankai","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,11,17]]},"reference":[{"key":"2877_CR1","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","volume":"26","author":"J Vose","year":"2008","unstructured":"Vose J, Armitage J, Weisenburger D (2008) International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 26:4124\u20134130","journal-title":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology"},{"key":"2877_CR2","doi-asserted-by":"crossref","first-page":"e214","DOI":"10.1038\/bcj.2014.34","volume":"4","author":"R Briski","year":"2014","unstructured":"Briski R, Feldman AL, Bailey NG et al (2014) The role of front-line anthracycline-containing chemotherapy regimens in peripheral T-cell lymphomas. Blood cancer journal 4:e214","journal-title":"Blood cancer journal"},{"key":"2877_CR3","doi-asserted-by":"crossref","first-page":"623924","DOI":"10.5402\/2011\/623924","volume":"2011","author":"AN Abouyabis","year":"2011","unstructured":"Abouyabis AN, Shenoy PJ, Sinha R, Flowers CR, Lechowicz MJ (2011) A systematic review and meta-analysis of front-line anthracycline-based chemotherapy regimens for peripheral T-cell lymphoma. ISRN hematology 2011:623924","journal-title":"ISRN hematology"},{"key":"2877_CR4","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1002\/ajh.23536","volume":"88","author":"JO Armitage","year":"2013","unstructured":"Armitage JO (2013) The aggressive peripheral T-cell lymphomas: 2013. Am J Hematol 88:910\u2013918","journal-title":"Am J Hematol"},{"key":"2877_CR5","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.ctrv.2014.08.001","volume":"40","author":"B Coiffier","year":"2014","unstructured":"Coiffier B, Federico M, Caballero D et al (2014) Therapeutic options in relapsed or refractory peripheral T-cell lymphoma. Cancer Treat Rev 40:1080\u20131088","journal-title":"Cancer Treat Rev"},{"key":"2877_CR6","doi-asserted-by":"crossref","first-page":"6756","DOI":"10.1182\/blood-2010-05-231548","volume":"117","author":"FM Foss","year":"2011","unstructured":"Foss FM, Zinzani PL, Vose JM, Gascoyne RD, Rosen ST, Tobinai K (2011) Peripheral T-cell lymphoma. Blood 117:6756\u20136767","journal-title":"Blood"},{"key":"2877_CR7","first-page":"512","volume":"72","author":"T Kinoshita","year":"2014","unstructured":"Kinoshita T (2014) Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS). Nihon rinsho Japanese journal of clinical medicine 72:512\u2013518","journal-title":"Nihon rinsho Japanese journal of clinical medicine"},{"key":"2877_CR8","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","volume":"17","author":"BD Cheson","year":"1999","unstructured":"Cheson BD, Horning SJ, Coiffier B et al (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 17:1244","journal-title":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology"},{"key":"2877_CR9","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1182\/blood-2003-09-3080","volume":"103","author":"A Gallamini","year":"2004","unstructured":"Gallamini A, Stelitano C, Calvi R et al (2004) Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood 103:2474\u20132479","journal-title":"Blood"},{"key":"2877_CR10","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1182\/blood-2010-09-310342","volume":"117","author":"DD Weisenburger","year":"2011","unstructured":"Weisenburger DD, Savage KJ, Harris NL et al (2011) Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project. Blood 117:3402\u20133408","journal-title":"Blood"},{"key":"2877_CR11","doi-asserted-by":"crossref","first-page":"320624","DOI":"10.1155\/2010\/320624","volume":"2010","author":"P Reimer","year":"2010","unstructured":"Reimer P (2010) Impact of autologous and allogeneic stem cell transplantation in peripheral T-cell lymphomas. Advances in hematology 2010:320624","journal-title":"Advances in hematology"},{"key":"2877_CR12","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ctrv.2012.03.011","volume":"39","author":"J Yared","year":"2013","unstructured":"Yared J, Kimball A (2013) The role of high dose chemotherapy and autologous stem-cell transplantation in peripheral T-cell lymphoma: a review of the literature and new perspectives. Cancer Treat Rev 39:51\u201359","journal-title":"Cancer Treat Rev"},{"key":"2877_CR13","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s12185-010-0614-9","volume":"92","author":"JM Zain","year":"2010","unstructured":"Zain JM, O'Connor O (2010) Targeted treatment and new agents in peripheral T-cell lymphoma. Int J Hematol 92:33\u201344","journal-title":"Int J Hematol"},{"key":"2877_CR14","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1093\/annonc\/mdp508","volume":"21","author":"PL Zinzani","year":"2010","unstructured":"Zinzani PL, Venturini F, Stefoni V et al (2010) Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome. Annals of oncology : official journal of the European Society for Medical Oncology \/ ESMO 21:860\u2013863","journal-title":"Annals of oncology : official journal of the European Society for Medical Oncology \/ ESMO"},{"key":"2877_CR15","doi-asserted-by":"crossref","first-page":"3535","DOI":"10.1007\/s12032-012-0309-6","volume":"29","author":"KL Yim","year":"2012","unstructured":"Yim KL, Ashley S (2012) Assessment of gemcitabine, cisplatin and methylprednisolone (GEM-P) combination treatment for non-Hodgkin T cell lymphoma. Medical oncology (Northwood, London, England) 29:3535\u20133539","journal-title":"Medical oncology (Northwood, London, England)"},{"key":"2877_CR16","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3324\/haematol.10737","volume":"92","author":"HT Arkenau","year":"2007","unstructured":"Arkenau HT, Chong G, Cunningham D et al (2007) Gemcitabine, cisplatin and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma: the Royal Marsden Hospital experience. Haematologica 92:271\u2013272","journal-title":"Haematologica"},{"key":"2877_CR17","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.3109\/10428194.2012.739286","volume":"54","author":"YY Yao","year":"2013","unstructured":"Yao YY, Tang Y, Zhu Q et al (2013) Gemcitabine, oxaliplatin and dexamethasone as salvage treatment for elderly patients with refractory and relapsed peripheral T-cell lymphoma. Leukemia & lymphoma 54:1194\u20131200","journal-title":"Leukemia & lymphoma"},{"key":"2877_CR18","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/cncr.27733","volume":"119","author":"D Mahadevan","year":"2013","unstructured":"Mahadevan D, Unger JM, Spier CM et al (2013) Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma: Southwest Oncology Group Study S0350. Cancer 119:371\u2013379","journal-title":"Cancer"},{"key":"2877_CR19","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s12032-012-0351-4","volume":"30","author":"M Dong","year":"2013","unstructured":"Dong M, He XH, Liu P et al (2013) Gemcitabine-based combination regimen in patients with peripheral T-cell lymphoma. Medical oncology (Northwood, London, England) 30:351","journal-title":"Medical oncology (Northwood, London, England)"},{"key":"2877_CR20","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1007\/s00277-015-2468-y","volume":"94","author":"BB Park","year":"2015","unstructured":"Park BB, Kim WS, Suh C et al (2015) Salvage chemotherapy of gemcitabine, dexamethasone, and cisplatin (GDP) for patients with relapsed or refractory peripheral T-cell lymphomas: a consortium for improving survival of lymphoma (CISL) trial. Ann Hematol 94:1845\u20131851","journal-title":"Ann Hematol"},{"key":"2877_CR21","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1200\/JCO.2012.44.7524","volume":"31","author":"V Mak","year":"2013","unstructured":"Mak V, Hamm J, Chhanabhai M et al (2013) Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 31:1970\u20131976","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"key":"2877_CR22","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","volume":"29","author":"OA O'Connor","year":"2011","unstructured":"O'Connor OA, Pro B, Pinter-Brown L et al (2011) Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 29:1182\u20131189","journal-title":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology"},{"key":"2877_CR23","unstructured":"Zinzani PL, Alinari L, Tani M et al (2005) Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma. Haematologica 90:702\u2013703"},{"key":"2877_CR24","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1093\/annonc\/mdv237","volume":"26","author":"Y Shi","year":"2015","unstructured":"Shi Y, Dong M, Hong X et al (2015) Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma. Annals of oncology : official journal of the European Society for Medical Oncology \/ ESMO 26:1766\u20131771","journal-title":"Annals of oncology : official journal of the European Society for Medical Oncology \/ ESMO"},{"key":"2877_CR25","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1756-8722-7-11","volume":"7","author":"B Coiffier","year":"2014","unstructured":"Coiffier B, Pro B, Prince HM et al (2014) Romidepsin for the treatment of relapsed\/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses. J Hematol Oncol 7:11","journal-title":"J Hematol Oncol"},{"key":"2877_CR26","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1200\/JCO.2014.59.2782","volume":"33","author":"OA O'Connor","year":"2015","unstructured":"O'Connor OA, Horwitz S, Masszi T et al (2015) Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 33:2492\u20132499","journal-title":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology"},{"key":"2877_CR27","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/bjh.13222","volume":"168","author":"F Foss","year":"2015","unstructured":"Foss F, Advani R, Duvic M et al (2015) A phase II trial of belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma. Br J Haematol 168:811\u2013819","journal-title":"Br J Haematol"},{"key":"2877_CR28","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1016\/j.ejca.2013.04.029","volume":"49","author":"F Morschhauser","year":"2013","unstructured":"Morschhauser F, Fitoussi O, Haioun C et al (2013) A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial. European journal of cancer (Oxford, England : 1990) 49:2869\u20132876","journal-title":"European journal of cancer (Oxford, England : 1990)"},{"key":"2877_CR29","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1200\/JCO.2012.43.7285","volume":"31","author":"G Damaj","year":"2013","unstructured":"Damaj G, Gressin R, Bouabdallah K et al (2013) Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 31:104\u2013110","journal-title":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology"},{"key":"2877_CR30","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s13045-016-0266-1","volume":"9","author":"C Pellegrini","year":"2016","unstructured":"Pellegrini C, Dodero A, Chiappella A et al (2016) A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed\/refractory peripheral T-cell lymphoma patients. J Hematol Oncol 9:38","journal-title":"J Hematol Oncol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-016-2877-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-016-2877-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-016-2877-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,25]],"date-time":"2017-06-25T03:50:49Z","timestamp":1498362649000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-016-2877-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,17]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["2877"],"URL":"https:\/\/doi.org\/10.1007\/s00277-016-2877-6","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,17]]}}}